Livongo Recognized by CDC

Livongo announced the Centers for Disease Control (CDC) granted Livongo “full recognition,” which recognizes diabetes prevention programs that meet a CDC-approved curriculum for duration, intensity, and reporting requirements. “Full recognition” is part of the CDC’s National Diabetes Prevention Program. Below, FENIX provides thoughts on how Livongo will likely leverage the CDC recognition to help aid uptake for its diabetes program.  Despite the advances in diabetes-related medications, the prevalence of T2DM continues to rise, which is why organizations like the CDC have endorsed technological solutions that focus on changing patient behavior. Livongo is clearly looking to leverage the increased CDC focus on diabetes to aid……

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.